Mohammad Tariq, MD
Pulmonary Disease · Kokomo, INNPI 1386792521
Payments from drug & device makers
Across 91 payments — averaging $17.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$274
- Boehringer Ingelheim$247
- AstraZeneca$162
- AbbVie$157
- Actelion Pharmaceuticals US, Inc.$110
- Grifols USA, LLC$98
- plus $547 from 14 others
What the payments were for
- Food & beverage$1,45891%
- Education$1379%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 28 | $274 |
| Boehringer Ingelheim | 9 | $247 |
| AstraZeneca | 10 | $162 |
| AbbVie | 6 | $157 |
| Actelion Pharmaceuticals US, Inc. | 3 | $110 |
| Grifols USA, LLC | 4 | $98 |
| Electromed, Inc. | 8 | $94 |
| Regeneron Healthcare Solutions, Inc. | 3 | $70 |
| Pfizer | 4 | $60 |
| Mallinckrodt Hospital Products Inc. | 2 | $54 |
| Advanced Respiratory, Inc | 3 | $49 |
| Genentech USA, Inc. | 1 | $48 |
| Johnson & Johnson | 2 | $33 |
| Pulmonx Corporation | 2 | $30 |
| Novartis | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Amgen | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Sanofi | 1 | $15 |
| Mylan Specialty L.p. | 1 | $14 |
How this compares
$1,595 in reported general payments places this provider in the 40th percentile of 258 pulmonary disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 821 | $757,015 |
| OfevNintedanib Esylate | 49 | $485,216 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 573 | $425,903 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 24 | $326,388 |
| Spiriva RespimatTiotropium Bromide | 224 | $177,650 |
| NucalaMepolizumab | 24 | $88,654 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 102 | $72,574 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 69 | $43,267 |
| Dupixent PenDupilumab | 11 | $40,829 |
| Breo ElliptaFluticasone/Vilanterol | 55 | $33,166 |
| Roflumilast | 556 | $32,223 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 76 | $31,596 |
| SymbicortBudesonide/Formoterol Fumarate | 68 | $24,544 |
| Spiriva HandihalerTiotropium Bromide | 27 | $23,351 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 767 | $17,756 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $274 | $937,3741,010 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat | $247 | $735,440375 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $162 | $450,446641 claims |
| Grifols USA, LLCProlastin C | $98 | $326,38824 claims |
| Teva Pharmaceuticals USA, Inc.Albuterol Sulfate | $20 | $1,41112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 258 pulmonary disease providers in Indiana.
Other pulmonary disease in Kokomo
- Cynthia BrownIndianapolis$7.3M
- Imad ShawaGreenwood$1.4M
- David MaresAnderson$1.3M
- Raja DevanathanHobart$862K
- Olusegun ApataGary$780K
- David WilsonSeymour$689K
- Giovanni InfusinoCrown Point$526K
- Faisal KhanGreenwood$400K
- Sandeep KukrejaGreenwood$375K
- Ajay DeshpandeTerre Haute$304K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.